Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer

NCT05662345 is registered in ClinicalTrials.gov with Menarini Silicon Biosystems, INC as lead sponsor.

NCT NCT05662345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05662345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer
Lead sponsor
Menarini Silicon Biosystems, INC
Phase
Observational
Overall status
Active, not recruiting
Start date
December 12, 2022
Completion date
October 31, 2026
Enrollment
65 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer